OUR SOLUTIONS / LARGE VESSEL STROKE

A patient-centric

approach to AIS

TIGERTRIEVER™ is the only active thrombectomy device– it is engineered to adapt to patient anatomy. Accelerate clot integration and reduce stress on the brain during mechanical thrombectomy procedures.

OUR SOLUTIONS / LVO

A patient-centric approach to AIS

TIGERTRIEVER™ is the only active thrombectomy device–it is engineered to adapt to patient anatomy. Accelerate clot integration and reduce stress on the brain during mechanical thrombectomy procedures.

Gain active

control 

Unlike conventional stent retrievers, active thrombectomy can improve clot penetration1 and facilitate smooth retrieval with adjustable radial force.

Gain active

control 

Unlike conventional stent retrievers, active thrombectomy can improve clot penetration1 and facilitate smooth retrieval with adjustable radial force.

Accelerate

thrombectomy

Two million brain cells die every minute. TIGERTRIEVER™ saves minutes when removing the clot– with reported procedure times faster than the leading competitors.

Speed matters – TIGER Trial showed quicker time to reperfusion than using aspiration alone.

Accelerate

thrombectomy

Two million brain cells die every minute.

TIGERTRIEVER saves minutes when removing the clot–with reported procedure times faster than the leading competitors.

Speed matters – TIGER Trial showed quicker time to reperfusion than using aspiration alone.


The 1st pass

should be the last

Adjustability handles patient variability in real-time. TIGERTRIEVER™ has high first-pass success (FPE) and low emboli to new territory (ENT), outperforming competitors in challenging procedures involving stenosis, hard clot, and tortuosity in patients with intracranial atherosclerosis (ICAD).

The 1st pass

should be the last

Adjustability handles patient variability in real-time. TIGERTRIEVER has high first-pass success (FPE) and low emboli to new territory (ENT), outperforming competitors in challenging procedures involving stenosis, hard clot, and tortuosity in patients with intracranial atherosclerosis (ICAD).

Click on a tab below to learn more.

Clinical evidence

PRODUCT OVERVIEW

The world’s first and only adjustable stent retriever, TIGERTRIEVER™ is designed with active, responsive technology for patient-specific procedures.

SPECIFICATIONS

Not all products are available in all countries.
Place an order Canada: orders.canada@rapid-medical.com
Ask a product question
Request an IFU

HOW IT WORKS

1
PENETRATE the clot with active integration
2
ADJUST with complete visibility
3
RELAX to relieve vessel traction
Place an order Canada: orders.canada@rapid-medical.com
Ask a product question
Request an IFU

WEBINARS

Physician-led webinars are available to view on-demand. To watch a recording, please submit a request here.

Request to view
Dr. Shahram Majidi – New York, NY
TIGERTRIEVER - A “next generation device”
View testimonial →
Dr. Rishi Gupta – Marietta, GA
First-pass TICI 3 following treatment with TIGERTRIEVER™
View the case →
Dr. Edgar Samaniego – SNIS Annual Meeting (2024)
TIGERTRIEVER™ in the treatment of acute ischemic stroke with underlying ICAD
Watch recording →
Place an order Canada: orders.canada@rapid-medical.com
Ask a product question
Request an IFU
×
×
×

Active thrombectomy tailors the procedure to the patient. 


Questions?

Reach out to learn more about our company and stroke solutions.

1. Sadasivan C, Dashti N, Gopal M, Serna RJ, Fiorella D. The effect of actuation frequency on clot integration with the Tigertriever device: A preliminary in vitro study. Interv Neuroradiol. Published online April 17, 2024. doi:10.1177/15910199241247886

2. Gupta, Rishi et al. “New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial.” Stroke vol. 52,5 (2021): 1534-1544. doi:10.1161/STROKEAHA.121.034436

3. Turk AS, Siddiqui A, Fifi JT, et al. Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial. Lancet. 2019;393:998-1008. doi:10.1016/S0140-6736(19)30297-1

4. Lapergue B, Blanc R, Gory B, et al. Effect of Endovascular Contact Aspiration vs Stent Retriever on Revascularization in Patients With Acute Ischemic Stroke and Large Vessel Occlusion: The ASTER Randomized Clinical Trial. JAMA. 2017;318(5):443-452. doi:10.1001/jama.2017.9644

5. Ojeda DJ, Ghannam M, Sanchez S, et al. Tigertriever in the treatment of acute ischemic stroke with underlying intracranial atherosclerotic disease. J Neurointerv Surg. 2024;16(11):1083-1087. Published 2024 Oct 14. doi:10.1136/jnis-2023-020796

6. Yi HJ, Sung JH, Lee DH, Song SY. Effectiveness and Technical Considerations of Solitaire Platinum 4×40 mm Stent Retriever in Mechanical Thrombectomy with Solumbra Technique. J Korean Neurosurg Soc. 2021;64(1):30-38. doi:10.3340/jkns.2020.0046

7. Kabbasch C, Mpotsaris A, Chang DH, et al. Mechanical thrombectomy with the Trevo ProVue device in ischemic stroke patients: does improved visibility translate into a clinical benefit?. J Neurointerv Surg. 2016;8(8):778-782. doi:10.1136/neurintsurg-2015-011861

8. Haussen DC, Al-Bayati AR, Grossberg JA, et al. Longer stent retrievers enhance thrombectomy performance in acute stroke. J Neurointerv Surg. 2019;11(1):6-8. doi:10.1136/neurintsurg-2018-013918